Table 2.
Multivariate regression analysis to identify correlates of breadth of neutralization
| Effect estimatea | 95% CI | p Value | |
|---|---|---|---|
| Neutralization titer against wildtype SARS-CoV-2 | 1.4 | 1.1 to 1.6 | <.001 |
| Age (per 5-year increase) | −0.09 | −0.17 to −0.01 | .029 |
| Vaccine type | |||
| mRNA1273 | Ref | ||
| BNT162b2 | −0.16 | −0.57 to 0.25 | .4 |
| Ad26.COV2.S | −0.29 | −0.77 to 0.18 | .2 |
| Chemotherapy | −0.14 | −0.50 to 0.22 | .4 |
| Immunotherapy | 0.16 | −0.30 to 0.62 | .5 |
| Time after first dose (per week) | 0.04 | 0.00 to 0.08 | .061 |
| Cancer type | |||
| Solid | Ref | ||
| Bone marrow transplanted | −0.04 | −0.55 to 0.47 | .9 |
| Hematologic | 0.2 | −0.42 to 0.81 | .5 |
a
Effect estimates shown are per additional variant neutralized at measurable levels (above the lower limit of detection).